Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have spe…
Biotechnology
US, Boston [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Vertex Pharmaceuticals Incorporated's gradings, price targets and earnings estimates.
Earnings
See the historical earnings and what wall street
analysts forecasted and
forecast for
future earnings.
Reported
Past Estimate Consensus
Future Estimate Consensus
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2014 | -1.9800 | -2.220 | 1,211 | 506 | -445 | -596 | 504 | -477 | -199 | -566 | 362 | 254 |
| 2015 | -3.1400 | -1.298 | 580 | 1,012 | -738 | -640 | -611 | -437 | -641 | -535 | 305 | 436 |
| 2016 | -2.3100 | 0.802 | 1,032 | 1,696 | -558 | -135 | -473 | 36 | -466 | -8 | 377 | 460 |
| 2017 | -0.4600 | 1.887 | 1,702 | 2,144 | -112 | 273 | 15 | 311 | 11 | 212 | 432 | 408 |
| 2018 | 1.0600 | 3.837 | 2,488 | 2,995 | 263 | 1,641 | 311 | 578 | 392 | 521 | 496 | 451 |
| 2019 | 8.2500 | 4.835 | 3,047 | 3,762 | 2,096 | 876 | 663 | 1,175 | 663 | 903 | 557 | 526 |
| 2020 | 4.5800 | 10.393 | 4,162 | 6,161 | 1,176 | 2,194 | 1,457 | 2,718 | 1,202 | 2,329 | 658 | 633 |
| 2021 | 10.4400 | 12.959 | 6,205 | 7,501 | 2,711 | 2,080 | 3,188 | 2,593 | 2,869 | 2,480 | 770 | 729 |
| 2022 | 9.0900 | 14.601 | 7,574 | 8,933 | 2,342 | 2,403 | 2,788 | 3,000 | 2,779 | 2,889 | 840 | 827 |
| 2023 | 12.9700 | 15.033 | 8,930 | 9,863 | 3,322 | 3,619 | 4,345 | 3,300 | 4,365 | 3,178 | 944 | 910 |
| 2024 | 14.0500 | 0.440 | 9,839 | 10,865 | 3,619 | 114 | 3,931 | 4,603 | 3,750 | 4,396 | 1,136 | 1,335 |
| 2025 | - | 18.877 | - | 11,759 | - | 4,273 | - | 4,981 | - | 4,758 | - | 1,445 |
| 2026 | - | 20.731 | - | 12,825 | - | 2.F12X/td> | - | 2.F121/td> | - | 2.F121 | - | 2.F121 |
| 2027 | - | 23.681 | - | 13,998 | - | 1.F13X/td> | - | 1.F131/td> | - | 1.F131 | - | 1.F131 |
| 2028 | - | 26.547 | - | 15,341 | - | 0.F14X/td> | - | 0.F141/td> | - | 0.F141 | - | 0.F141 |
Institutional Sentiment
Wall Street · Earnings · Institutional Sentiment
Morgan Stanley
1Y Ago:
Equal-Weight
Prev. Grade
Equal-Weight
Nov. 6, 2024
Equal-Weight
JP Morgan Chase
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
Citigroup
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
Overall Consensus
Grading Consensus
Click to each, to see the gradePrice Target Consensus
-14.521% $65.40 · MISS
Nov. 6, 2024Price Then
$499.88
Price Target
$515.77
Price Now
$450.37